DiogenX is a preclinical stage biotech company focused on developing pancreatic beta-cell modulators as regenerative treatments for type 1 diabetes. The company aims to provide new therapeutic options for millions of diabetic patients by targeting the underlying mechanisms of insulin production and secretion.
Funding
$34.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Type 1 diabetes results from the autoimmune destruction of pancreatic beta cells, leading to insulin deficiency and lifelong dependence on exogenous insulin. Current treatments manage blood glucose levels but do not address the underlying cause of beta-cell loss or restore endogenous insulin production. This unmet need leaves millions of patients vulnerable to long-term complications.
Solution
DiogenX is developing regenerative biologics that modulate pancreatic beta-cell function to restore insulin production in patients with type 1 diabetes. Their approach focuses on identifying and developing first-in-class molecules that can protect and regenerate beta cells, addressing the root cause of the disease. By targeting the underlying mechanisms of insulin production and secretion, DiogenX aims to provide new therapeutic options that can reduce or eliminate the need for insulin injections and improve long-term outcomes for diabetic patients.
Target Audience
The primary target audience includes individuals diagnosed with type 1 diabetes and the healthcare professionals who treat them, such as endocrinologists and diabetes specialists.
Features
- Focus on innovative biologics for beta-cell regeneration
- Development of first-in-class regenerative treatments for type 1 diabetes
- Targeting the underlying mechanisms of insulin production and secretion